Allogene Therapeutics, Inc.
ALLOAllogene Therapeutics, Inc. in brief
Allogene Therapeutics, Inc. is a listed company in the Biotechnology industry, based in South San Francisco, California, USA. It was founded in 2017. Its market value was $450 M on 29 October 2026, which makes it the 13,047th largest listed company in the world and the 2,599th largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $191 M. It employs about 310 people and Zachary Roberts is its chief executive. Its largest business segments by sales in 2024 were Reportable (100%). Its shares trade under the symbol ALLO (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Allogene Therapeutics, Inc.
Allogene Therapeutics is a Clinical Stage Biotechnology company. It single minded focus on pioneering the development of allogeneic chimeric antigen receptor T cell therapies for cancer and researchers is dedicated to discovery and translational research, development and cell manufacturing. The headquarters is in USA.
Allogene Therapeutics, Inc. timeline
- 2017
- 🏁· approximateFounded
- 2018
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 11 October 2018; shares registered for exchange trading on 5 October 2018.
Events of Allogene Therapeutics, Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #1,179 (Jan 2020) · #1,236 (Jan 2021) · #1,901 (Jan 2022) · #2,129 (Dec 2022) · #2,381 (Jul 2023) · #2,426 (Jan 2024) · #1,215 (Mar 2026) · #2,312 (Aug 2026) · #2,537 (Oct 2026) · #2,603 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 1.5×
- Free cash flow yield
- -33.2%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -65.3%
- Liabilities / assets
- 29.7%
- Revenue growth
- -80.0%
- R&D / revenue
- 961500.0%
- Revenue per employee
- $0 K
- Profit per employee
- $-616 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-209M | $-191M | — |
| Dec 2024 | $0M | -80.0% | $-273M | $-258M | -1287950.0% |
| Dec 2023 | $0M | -37.5% | $-328M | $-327M | -327260.0% |
| Dec 2022 | $0M | -99.9% | $-336M | $-340M | -212756.3% |
| Dec 2021 | $114M | — | $-180M | $-182M | -159.6% |
| Dec 2020 | — | — | $-258M | $-316M | — |
| Dec 2019 | — | — | $-202M | $-185M | — |
| Dec 2018 | — | — | $-193M | $-212M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-149M | $0M | $-150M | $-0.87 | $0.00 |
| Dec 2024 | $-200M | $1M | $-201M | $-1.32 | $0.00 |
| Dec 2023 | $-238M | $2M | $-239M | $-2.09 | $0.00 |
| Dec 2022 | $-221M | $5M | $-226M | $-2.38 | $0.00 |
| Dec 2021 | $-185M | $21M | $-206M | $-1.34 | $0.00 |
| Dec 2020 | $-115M | $66M | $-181M | $-2.63 | $0.00 |
| Dec 2019 | $-137M | $51M | $-188M | $-1.83 | $0.00 |
| Dec 2018 | $-45M | $3M | $-48M | $-7.31 | $0.00 |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-50M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 6, 202610-QQuarterly report · period to Sep 2026
- Nov 5, 20268-KCurrent reportResults of operations
- Sep 2, 20268-KCurrent reportDirectors or officers changed
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Aug 12, 20268-KCurrent reportResults of operations
- Jun 22, 20268-KCurrent reportShareholder vote · Other events
- May 28, 20268-KCurrent reportDirectors or officers changed
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 13, 20268-KCurrent reportMaterial agreement · Agreement ended · Results of operations
- Apr 30, 2026DEF 14AProxy statement
- Apr 15, 20268-KCurrent reportOther events
- Apr 13, 20268-KCurrent reportOther events
Official filings of Allogene Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $0 M
- Operating income
- $-209 M
- Net income
- $-191 M
For year ending December-2025
Balance sheet
- Total assets
- $416 M
- Total liabilities
- $123 M
- Total equity
- $293 M
As of December-2025
Top 100 institutional investors in Allogene Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 30,927,343 | +780,380 (+2.59%) | 8.93% | $49 M | Nov 13, 2026 |
| 2 | Citadel Advisors LLC | 24,558,325 | +14,470,555 (+143.45%) | 7.09% | $39 M | Nov 16, 2026 |
| 3 | Frazier Life Sciences Management, L.P. | 22,446,668 | 0 (0.00%) | 6.48% | $36 M | Nov 16, 2026 |
| 4 | Pfizer Inc | 22,032,040 | 0 (0.00%) | 6.36% | $35 M | Nov 12, 2026 |
| 5 | State Street Corp | 16,326,197 | -2,699,629 (-14.19%) | 4.71% | $26 M | Nov 12, 2026 |
| 6 | Primecap Management Co/ca/ | 13,146,840 | +23,400 (+0.18%) | 3.79% | $21 M | Nov 12, 2026 |
| 7 | Vanguard Capital Management LLC | 12,050,271 | -116,365 (-0.96%) | 3.48% | $19 M | Nov 13, 2026 |
| 8 | UBS Group AG | 10,704,296 | +7,665,904 (+252.30%) | 3.09% | $17 M | Nov 10, 2026 |
| 9 | FMR LLC | 10,599,559 | -1,409,484 (-11.74%) | 3.06% | $17 M | Nov 10, 2026 |
| 10 | Sio Capital Management, LLC | 9,104,151 | -4,219,280 (-31.67%) | 2.63% | $15 M | Nov 16, 2026 |
| 11 | Two Sigma Investments, LP | 9,012,677 | +1,228,329 (+15.78%) | 2.60% | $14 M | Nov 16, 2026 |
| 12 | Marshall Wace, LLP | 7,973,647 | +2,878,239 (+56.49%) | 2.30% | $13 M | Nov 13, 2026 |
| 13 | Geode Capital Management, LLC | 6,446,801 | -602,527 (-8.55%) | 1.86% | $10 M | Nov 6, 2026 |
| 14 | Candriam S.C.A. | 5,422,820 | +1,086,524 (+25.06%) | 1.57% | $9 M | Nov 3, 2026 |
| 15 | Goldman Sachs Group Inc | 5,330,283 | -818,676 (-13.31%) | 1.54% | $9 M | Nov 16, 2026 |
| 16 | GordonMD Global Investments LP | 5,298,000 | 0 (0.00%) | 1.53% | $8 M | Nov 16, 2026 |
| 17 | Aberdeen Group plc | 5,259,681 | +257,929 (+5.16%) | 1.52% | $8 M | Nov 10, 2026 |
| 18 | Renaissance Technologies LLC | 5,232,012 | +1,397,700 (+36.45%) | 1.51% | $8 M | Nov 12, 2026 |
| 19 | Millennium Management LLC | 5,115,535 | +271,646 (+5.61%) | 1.48% | $8 M | Nov 16, 2026 |
| 20 | Patient Square Capital LP | 4,550,000 | -500,000 (-9.90%) | 1.31% | $7 M | Nov 10, 2026 |
| 21 | D. E. Shaw & Co., Inc. | 4,261,315 | -449,420 (-9.54%) | 1.23% | $7 M | Nov 16, 2026 |
| 22 | Vanguard Portfolio Management LLC | 3,861,920 | -350,158 (-8.31%) | 1.11% | $6 M | Nov 13, 2026 |
| 23 | HRT Financial LP | 3,345,358 | -276,221 (-7.63%) | 0.97% | $5 M | Nov 13, 2026 |
| 24 | Morgan Stanley | 3,327,315 | -1,182,647 (-26.22%) | 0.96% | $5 M | Nov 13, 2026 |
| 25 | RTW Investments, LP | 3,250,000 | 0 (0.00%) | 0.94% | $5 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Dimensional Fund Advisors LP | 3,202,488 | -36,589 (-1.13%) | 0.92% | $5 M | Nov 4, 2026 |
| 27 | Wildcat Capital Management, LLC | 2,920,787 | 0 (0.00%) | 0.84% | $5 M | Oct 28, 2026 |
| 28 | Woodline Partners LP | 2,810,624 | -1,690,000 (-37.55%) | 0.81% | $4 M | Nov 16, 2026 |
| 29 | Northern Trust Corp | 2,809,197 | -146,085 (-4.94%) | 0.81% | $4 M | Nov 16, 2026 |
| 30 | Ameriprise Financial Inc | 2,613,430 | +2,143,564 (+456.21%) | 0.75% | $4 M | Nov 16, 2026 |
| 31 | Charles Schwab Investment Management Inc | 2,370,314 | +95,951 (+4.22%) | 0.68% | $4 M | Nov 16, 2026 |
| 32 | Acadian Asset Management LLC | 2,223,697 | +1,905,331 (+598.47%) | 0.64% | $4 M | Nov 9, 2026 |
| 33 | Walleye Capital LLC | 2,205,649 | -1,062,363 (-32.51%) | 0.64% | $4 M | Nov 13, 2026 |
| 34 | Bank Of America Corp /de/ | 2,007,897 | -1,179,423 (-37.00%) | 0.58% | $3 M | Nov 16, 2026 |
| 35 | DAFNA Capital Management LLC | 2,000,000 | 0 (0.00%) | 0.58% | $3 M | Nov 16, 2026 |
| 36 | Vanguard Fiduciary Trust Co | 1,804,543 | -33,801 (-1.84%) | 0.52% | $3 M | Nov 13, 2026 |
| 37 | Boxer Capital Management, LLC | 1,500,000 | 0 (0.00%) | 0.43% | $2 M | Nov 16, 2026 |
| 38 | Price T Rowe Associates Inc /MD/ | 1,449,861 | -3,189,422 (-68.75%) | 0.42% | $2 M | Nov 16, 2026 |
| 39 | Jpmorgan Chase & Co | 1,420,277 | -18,157 (-1.26%) | 0.41% | $2 M | Nov 12, 2026 |
| 40 | Qube Research & Technologies Ltd | 1,178,377 | New | 0.34% | $2 M | Nov 13, 2026 |
| 41 | Connor, Clark & Lunn Investment Management Ltd. | 1,117,103 | +794,276 (+246.04%) | 0.32% | $2 M | Nov 10, 2026 |
| 42 | Raiffeisen Bank International AG | 1,100,000 | 0 (0.00%) | 0.32% | $2 M | Oct 28, 2026 |
| 43 | Hennion & Walsh Asset Management, Inc. | 1,039,328 | +316,400 (+43.77%) | 0.30% | $2 M | Oct 13, 2026 |
| 44 | Ghisallo Capital Management LLC | 1,000,000 | -2,000,000 (-66.67%) | 0.29% | $2 M | Nov 16, 2026 |
| 45 | Invesco Ltd. | 843,967 | +71,181 (+9.21%) | 0.24% | $1 M | Nov 12, 2026 |
| 46 | Bank of New York Mellon Corp | 749,988 | +22,806 (+3.14%) | 0.22% | $1 M | Nov 5, 2026 |
| 47 | Raymond James Financial Inc | 652,543 | -26,429 (-3.89%) | 0.19% | $1 M | Nov 12, 2026 |
| 48 | Nuveen, LLC | 627,956 | +3,308 (+0.53%) | 0.18% | $1 M | Nov 10, 2026 |
| 49 | Mitsubishi UFJ Asset Management Co., Ltd. | 546,210 | -979 (-0.18%) | 0.16% | $1 M | Nov 5, 2026 |
| 50 | Gsa Capital Partners LLP | 542,723 | +257,133 (+90.04%) | 0.16% | $1 M | Nov 16, 2026 |
| 51 | Man Group plc | 518,882 | -183,019 (-26.07%) | 0.15% | $1 M | Nov 16, 2026 |
| 52 | Franklin Templeton Inc | 483,157 | New | 0.14% | $1 M | Nov 12, 2026 |
| 53 | Alps Advisors Inc | 454,472 | +104,169 (+29.74%) | 0.13% | $1 M | Nov 3, 2026 |
| 54 | Creative Planning | 453,806 | +27,369 (+6.42%) | 0.13% | $1 M | Nov 2, 2026 |
| 55 | Rafferty Asset Management, LLC | 401,856 | +64,321 (+19.06%) | 0.12% | $1 M | Nov 13, 2026 |
| 56 | BIT Capital GmbH | 388,000 | +158,000 (+68.70%) | 0.11% | $1 M | Nov 13, 2026 |
| 57 | Squarepoint Ops LLC | 376,940 | +135,416 (+56.07%) | 0.11% | $1 M | Nov 9, 2026 |
| 58 | Point72 Asset Management, L.P. | 368,461 | New | 0.11% | $1 M | Nov 16, 2026 |
| 59 | Rhumbline Advisers | 335,212 | +25,471 (+8.22%) | 0.10% | $1 M | Nov 10, 2026 |
| 60 | Voleon Capital Management LP | 309,220 | -176,401 (-36.32%) | 0.09% | $0 M | Nov 16, 2026 |
| 61 | Citigroup Inc | 308,864 | -206,635 (-40.08%) | 0.09% | $0 M | Nov 4, 2026 |
| 62 | Harold Davidson & Associates Inc. | 281,434 | -88 (-0.03%) | 0.08% | $0 M | Oct 29, 2026 |
| 63 | Empirical Financial Services, LLC d.b.a. Empirical Wealth Management | 279,259 | New | 0.08% | $0 M | Oct 27, 2026 |
| 64 | AQR Capital Management LLC | 261,324 | -1,744,964 (-86.97%) | 0.08% | $0 M | Nov 16, 2026 |
| 65 | Ieq Capital, LLC | 258,440 | -321,931 (-55.47%) | 0.07% | $0 M | Nov 10, 2026 |
| 66 | HSBC Holdings PLC | 248,329 | -11,418 (-4.40%) | 0.07% | $0 M | Nov 16, 2026 |
| 67 | Deutsche Bank AG\ | 248,091 | -33,858 (-12.01%) | 0.07% | $0 M | Nov 6, 2026 |
| 68 | Susquehanna International Group, LLP | 231,290 | +137,649 (+147.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 69 | Barclays PLC | 228,375 | +8,657 (+3.94%) | 0.07% | $0 M | Nov 6, 2026 |
| 70 | Alliancebernstein L.P. | 225,878 | 0 (0.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 71 | LPL Financial LLC | 220,600 | -70 (-0.03%) | 0.06% | $0 M | Nov 6, 2026 |
| 72 | Cerity Partners LLC | 213,338 | -116,952 (-35.41%) | 0.06% | $0 M | Nov 13, 2026 |
| 73 | Canada Pension Plan Investment Board | 204,500 | +89,000 (+77.06%) | 0.06% | $0 M | Nov 16, 2026 |
| 74 | XTX Topco Ltd | 203,752 | +172,829 (+558.90%) | 0.06% | $0 M | Nov 16, 2026 |
| 75 | American Century Companies Inc | 194,180 | -13,224 (-6.38%) | 0.06% | $0 M | Nov 12, 2026 |
| 76 | Mason & Associates Inc | 174,761 | New | 0.05% | $0 M | Nov 16, 2026 |
| 77 | Manufacturers Life Insurance Company, The | 174,453 | -251,821 (-59.07%) | 0.05% | $0 M | Nov 13, 2026 |
| 78 | OpenArc Corporate Advisory, LLC | 174,258 | 0 (0.00%) | 0.05% | $0 M | Oct 21, 2026 |
| 79 | BFC Planning, Inc. | 173,000 | New | 0.05% | $0 M | Nov 13, 2026 |
| 80 | Quadrature Capital Ltd | 171,735 | -38,758 (-18.41%) | 0.05% | $0 M | Nov 13, 2026 |
| 81 | Virtus Investment Advisers, LLC | 167,018 | -5,191 (-3.01%) | 0.05% | $0 M | Nov 12, 2026 |
| 82 | Partners Capital Investment Group, LLP | 161,597 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 83 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 159,832 | -1,606 (-0.99%) | 0.05% | $0 M | Nov 16, 2026 |
| 84 | TD Asset Management Inc | 154,680 | -307,400 (-66.53%) | 0.04% | $0 M | Nov 13, 2026 |
| 85 | Indivisible Partners | 147,000 | New | 0.04% | $0 M | Oct 26, 2026 |
| 86 | Nomura Asset Management International Inc. | 146,779 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 87 | Royal Bank Of Canada | 145,390 | -41,037 (-22.01%) | 0.04% | $0 M | Nov 16, 2026 |
| 88 | Profund Advisors LLC | 141,379 | -28,319 (-16.69%) | 0.04% | $0 M | Oct 29, 2026 |
| 89 | Choreo, LLC | 137,212 | +12,150 (+9.72%) | 0.04% | $0 M | Oct 28, 2026 |
| 90 | CANADA LIFE ASSURANCE Co | 131,320 | +55,371 (+72.91%) | 0.04% | $0 M | Nov 13, 2026 |
| 91 | MetLife Investment Management, LLC | 131,119 | -25,056 (-16.04%) | 0.04% | $0 M | Nov 16, 2026 |
| 92 | Brevan Howard Capital Management LP | 125,630 | +86,612 (+221.98%) | 0.04% | $0 M | Nov 16, 2026 |
| 93 | Russell Investments Group, Ltd. | 123,601 | -314,808 (-71.81%) | 0.04% | $0 M | Nov 6, 2026 |
| 94 | Bridgeway Capital Management, LLC | 122,895 | -127,105 (-50.84%) | 0.04% | $0 M | Nov 16, 2026 |
| 95 | Empowered Funds, LLC | 122,895 | New | 0.04% | $0 M | Nov 13, 2026 |
| 96 | SEI Investments Co | 115,919 | +67,599 (+139.90%) | 0.03% | $0 M | Nov 10, 2026 |
| 97 | Smartleaf Asset Management LLC | 115,690 | -22,184 (-16.09%) | 0.03% | $0 M | Nov 10, 2026 |
| 98 | Vanguard Global Advisers, LLC | 101,051 | -114,134 (-53.04%) | 0.03% | $0 M | Nov 13, 2026 |
| 99 | BNP Paribas Financial Markets | 98,750 | +41,991 (+73.98%) | 0.03% | $0 M | Nov 12, 2026 |
| 100 | Engineers Gate Manager LP | 89,389 | -9,122 (-9.26%) | 0.03% | $0 M | Nov 16, 2026 |
Mutual funds holding Allogene Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc. | 12.14 M | $25 M | 3.5% | 0.24% | +133% | Jun 30, 2026 |
| 🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC | 9.55 M | $21 M | 2.8% | 0.39% | +581% | May 31, 2026 |
| 🇺🇸 Vanguard Capital Opportunity FundPRIMECAP Management Company | 9.39 M | $20 M | 2.7% | 0.06% | +75% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 8.67 M | $18 M | 2.5% | <0.01% | +78% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 6.92 M | $14 M | 2.0% | 0.02% | +80% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc. | 3.44 M | $7 M | 0.99% | 0.06% | −10% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 3.22 M | $7 M | 0.93% | <0.01% | +71% | Jun 30, 2026 |
| 🇺🇸 PRIMECAP Odyssey Aggressive Growth FundPRIMECAP Management Company | 3.48 M | $7 M | 1.0% | 0.09% | +3.0% | Jul 31, 2026 |
| 🇺🇸 abrdn Life Sciences Investorsabrdn Inc. | 2.73 M | $6 M | 0.79% | 0.82% | +87% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 2.91 M | $5 M | 0.84% | 0.02% | +88% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 2.48 M | $5 M | 0.72% | 0.04% | +83% | Jun 30, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 1.80 M | $4 M | 0.52% | 0.04% | +57% | Jun 30, 2026 |
| 🇺🇸 abrdn Healthcare Investorsabrdn Inc. | 1.77 M | $4 M | 0.51% | 0.27% | new | Jun 30, 2026 |
| 🇺🇸 Columbia Small Cap Value Discovery FundColumbia Management Investment Advisers, LLC | 1.80 M | $3 M | 0.52% | 0.14% | new | Jul 31, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC | 1.44 M | $3 M | 0.42% | 0.06% | new | May 29, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 1.44 M | $3 M | 0.42% | 0.05% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 1.32 M | $3 M | 0.38% | <0.01% | +52% | May 31, 2026 |
| 🇺🇸 State Street SPDR S&P Kensho New Economies Composite ETFSSGA Funds Management, Inc. | 1.31 M | $3 M | 0.38% | 0.10% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC | 1.21 M | $3 M | 0.35% | 0.04% | no change | May 29, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 1.21 M | $3 M | 0.35% | 0.01% | +53% | May 31, 2026 |
| 🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc. | 1.16 M | $2 M | 0.33% | 0.08% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 1.03 M | $2 M | 0.30% | 0.01% | +17% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 799,026 | $2 M | 0.23% | <0.01% | +4.6% | May 31, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 743,762 | $2 M | 0.21% | <0.01% | +64% | May 31, 2026 |
| 🇺🇸 Small Cap Value FundNorthern Trust Investments, Inc. | 631,204 | $1 M | 0.18% | 0.19% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 665,641 | $1 M | 0.19% | <0.01% | +408% | Jul 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 665,494 | $1 M | 0.19% | 0.02% | +224% | Jul 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 645,365 | $1 M | 0.19% | 0.02% | +89% | Jul 31, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 588,543 | $1 M | 0.17% | 0.04% | +6.3% | Jul 31, 2026 |
| 🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc. | 496,849 | $1 M | 0.14% | 0.06% | new | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 476,775 | $1 M | 0.14% | <0.01% | +46% | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 496,148 | $1 M | 0.14% | 0.02% | +89% | Jun 30, 2026 |
| 🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I | 469,495 | $1 M | 0.14% | 0.08% | new | May 31, 2026 |
| 🇺🇸 iShares U.S. Small-Cap Equity Factor ETFBlackRock Fund Advisors | 476,459 | $1 M | 0.14% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 407,995 | $1 M | 0.12% | <0.01% | −59% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 386,508 | $1 M | 0.11% | <0.01% | +66% | May 31, 2026 |
| 🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC | 412,615 | $1 M | 0.12% | 0.16% | +36% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 372,025 | $1 M | 0.11% | 0.04% | +92% | Jun 30, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 353,956 | $1 M | 0.10% | <0.01% | +2.4% | Jun 30, 2026 |
| 🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC | 344,966 | $1 M | 0.10% | 0.07% | −1.1% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 352,649 | $1 M | 0.10% | 0.02% | +107% | Jul 31, 2026 |
| 🇺🇸 NVIT Multi-Manager Small Company FundNATIONWIDE FUND ADVISORS | 304,265 | $1 M | 0.09% | 0.14% | +117% | Jun 30, 2026 |
| 🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc. | 295,178 | $1 M | 0.09% | 0.05% | −5.7% | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 288,539 | $1 M | 0.08% | 0.02% | +65% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Value FundNATIONWIDE FUND ADVISORS | 277,844 | $1 M | 0.08% | 0.26% | +130% | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 250,000 | $1 M | 0.07% | 0.35% | no change | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc. | 243,268 | $1 M | 0.07% | 0.07% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 241,276 | $0 M | 0.07% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 204,346 | $0 M | 0.06% | 0.02% | new | May 31, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 219,943 | $0 M | 0.06% | <0.01% | +334% | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 191,000 | $0 M | 0.06% | 0.02% | +104% | Jun 30, 2026 |
| 🇺🇸 Small Cap Equity FundGuideStone Capital Management, LLC | 182,977 | $0 M | 0.05% | 0.04% | −14% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 167,572 | $0 M | 0.05% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 165,591 | $0 M | 0.05% | 0.05% | +23% | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds | 165,491 | $0 M | 0.05% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 149,554 | $0 M | 0.04% | <0.01% | +13% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 149,004 | $0 M | 0.04% | <0.01% | +67% | Jun 30, 2026 |
| 🇺🇸 Nomura Healthcare FundDelaware Management Company | 146,779 | $0 M | 0.04% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 162,243 | $0 M | 0.05% | <0.01% | +89% | Jul 31, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 140,441 | $0 M | 0.04% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 137,154 | $0 M | 0.04% | 0.02% | +78% | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 148,999 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 128,181 | $0 M | 0.04% | <0.01% | +83% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 119,752 | $0 M | 0.03% | 0.02% | +7.1% | May 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 126,787 | $0 M | 0.04% | 0.02% | +87% | Jul 31, 2026 |
| 🇺🇸 BlackRock Health Sciences TrustBlackRock Advisors, LLC | 104,283 | $0 M | 0.03% | 0.04% | −1.1% | Jun 30, 2026 |
| 🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC | 94,053 | $0 M | 0.03% | 0.11% | — | Apr 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 103,519 | $0 M | 0.03% | <0.01% | +74% | Jul 31, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 88,543 | $0 M | 0.03% | 0.02% | +76% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 87,072 | $0 M | 0.03% | 0.02% | +153% | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 81,731 | $0 M | 0.02% | <0.01% | +59% | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 78,774 | $0 M | 0.02% | <0.01% | +21% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 76,123 | $0 M | 0.02% | 0.02% | +103% | Jun 30, 2026 |
| 🇺🇸 Acuitas US Microcap FundAcuitas Investments, LLC | 73,908 | $0 M | 0.02% | 0.13% | — | Jun 30, 2026 |
| 🇺🇸 JPMorgan Small Cap Value PortfolioBrighthouse Investment Advisers, LLC | 72,609 | $0 M | 0.02% | 0.05% | −14% | Jun 30, 2026 |
| 🇺🇸 Health Sciences PortfolioPacific Life Fund Advisors LLC | 72,554 | $0 M | 0.02% | 0.04% | −1.1% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 72,032 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC | 70,293 | $0 M | 0.02% | 0.06% | −44% | Jun 30, 2026 |
| 🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC | 68,948 | $0 M | 0.02% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 62,314 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP | 71,758 | $0 M | 0.02% | <0.01% | +13% | Jul 31, 2026 |
| 🇺🇸 Small Cap Value FundThe Variable Annuity Life Insurance Company | 60,126 | $0 M | 0.02% | 0.05% | new | May 31, 2026 |
| 🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC | 59,892 | $0 M | 0.02% | 0.07% | −35% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 58,841 | $0 M | 0.02% | 0.02% | +98% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 54,998 | $0 M | 0.02% | 0.02% | +94% | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 49,800 | $0 M | 0.01% | <0.01% | +5.1% | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 47,676 | $0 M | 0.01% | 0.01% | +18% | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 47,322 | $0 M | 0.01% | <0.01% | +115% | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 41,656 | $0 M | 0.01% | 0.02% | +92% | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 41,487 | $0 M | 0.01% | 0.02% | +73% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 40,481 | $0 M | 0.01% | 0.02% | +106% | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 43,507 | $0 M | 0.01% | 0.02% | +75% | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 35,848 | $0 M | 0.01% | 0.02% | +70% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 32,767 | $0 M | <0.01% | <0.01% | −23% | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 31,512 | $0 M | <0.01% | 0.02% | +95% | Jun 30, 2026 |
| 🇺🇸 AVIP BlackRock Advantage Small Cap Growth PortfolioCONSTELLATION INVESTMENTS INC | 28,341 | $0 M | <0.01% | 0.04% | −11% | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 31,081 | $0 M | <0.01% | 0.02% | +84% | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 29,521 | $0 M | <0.01% | <0.01% | +72% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 24,956 | $0 M | <0.01% | <0.01% | −0.8% | Jun 30, 2026 |
| 🇺🇸 EQ/Common Stock Index PortfolioEquitable Investment Management Group, LLC | 24,600 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Allogene Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Geoffrey M. ParkerCHIEF FINANCIAL OFFICER | Sell | -36,342 | $1.340 | $49 K | 1.05 M | Form 4 |
| filed | Earl Martin DouglasSVP, General Counsel | Sell | -29,697 | $2.120 | $63 K | 488,267 | Form 4 |
| filed | Joshua A. KazamDirector | Option exercise | +47,700 | — | — | 398,463 | Form 4 |
| filed | Annie YoshiyamaSVP, Finance | Sell | -9,586 | $2.310 | $22 K | 124,517 | Form 4 |
| filed | Benjamin Machinas BeneskiSVP, Chief Technical Officer | Sell | -2,867 | $2.500 | $7 K | 195,338 | Form 4 |
| filed | Benjamin Machinas BeneskiSVP, Chief Technical Officer | Sell | -4,835 | $2.470 | $12 K | 198,205 | Form 4 |
| filed | David D. ChangPresident and CEO, Director | Sell | -47,763 | $2.470 | $118 K | 5.15 M | Form 4 |
| filed | Benjamin Machinas BeneskiSVP, Chief Technical Officer | Sell | -7,132 | $2.600 | $19 K | 203,040 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Allogene Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-5.25 reverse split
Trading halts
- 2026-04-13 11:25 UTC, code T3, resumed 12:00 UTC
- 2025-02-19 14:31 UTC, code LUDP, resumed 14:41 UTC
Fails to deliver
- : 875,974 shares at $1.30
- : 189,481 shares at $1.23
- : 666,195 shares at $1.21
- : 9,223 shares at $1.25
- : 1 shares at $1.31
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Allogene Therapeutics, Inc. scorecard#
Passes 3 of the 14 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 29, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.5×Price to book 1.5× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-33.2%Free cash flow is -33.2% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.87 vs -1.32Diluted EPS -0.87 in fiscal 2025 against -1.32 the year before (report's currency).
- ✓Net income higher than five years earlier-$191 M-$191 M in fiscal 2025 against -$316 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$191 MNet income -$191 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-53.4%-53.4% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities7.9×Current ratio 7.93 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 3
- ✗Pays a dividendNoNo dividends in fiscal 2025.
- ✗Dividend per share raised five years in a row0 of 5Dividend per share raised in 0 of the five years to fiscal 2025.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year13.2%Diluted shares up 13.2% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Allogene Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 0−100%— | 0.0−76.8%100% | 0.1−39.1%100% | 0.2r0.2−99.9%100% | 114r38—100% | 0—— | 0—— | — | |
| Research and development | 150−21.9%— | 192−20.8%874086% | 243−5.3%255699% | 256+16.4%164351% | 220+14.1%193% | 193+33.5%— | 145−4.8%— | 152—— | |
| General and administrative | 57−12.9%— | 65−9.0%296386% | 72−9.6%75445% | 79+7.0%50837% | 74+13.6%65.0% | 65+13.5%— | 57+40.2%— | 41—— | |
| Operating expenses | 209−23.4%— | 273−16.7%1241914% | 328−2.3%345086% | 336+14.1%215187% | 294+14.0%258% | 258+27.8%— | 202+4.8%— | 193—— | |
| Operating income | −209—— | −273—−1241814% | −328—−344986% | −336r−335—−215087% | −180r−256—−158% | −258—— | −202—— | −193—— | |
| Interest expense and finance costs | 1.1+494%— | 0.2—823% | 0—0.0% | — | — | 0—— | 0−100%— | 3.4—— | |
| Share of profit of associates | 0—— | −1.7—−7673% | −11—−11234% | — | — | — | — | — | |
| Other non-operating income (expense) | 18+14.8%— | 16+3301%72964% | 0.5—497% | −4.9r2.8—−3127% | −1.9r−1.2—−1.6% | −58r8.0−440%— | 17—— | −19—— | |
| Income before tax | −191—— | −257—−1168850% | −327—−344489% | — | −257—−225% | −250—— | −185—— | −212—— | |
| Income tax | 0−100%— | 0.4—2014% | 0—0.0% | 0—0.0% | 0—0.0% | 0—— | −0.3—— | −0.1—— | |
| Net income including minority interests | −191—— | −258—−1170864% | −327—−344489% | −340r−333—−218214% | −182r−257—−160% | −316r−250—— | −185—— | −212—— | |
| Net income attributable to shareholders | −191—— | −258—−1170864% | −327—−344489% | −340r−333—−218214% | −182r−257—−160% | −316r−250—— | −185—— | −212—— | |
| Earnings per share, basic | -0.87—— | -1.32—— | -2.09—— | -2.38r-2.32—— | -1.34r-1.89—— | -2.63r-2.08—— | -1.83—— | -7.31—— | |
| Earnings per share, diluted | -0.87—— | -1.32—— | -2.09—— | -2.38r-2.32—— | -1.34r-1.89—— | -2.63r-2.08—— | -1.83—— | -7.31—— | |
| Shares, weighted average (basic) | 221+13.2%— | 195+24.1%— | 157+9.6%— | 143+5.4%— | 136+12.8%— | 120+19.1%— | 101—— | — | |
| Shares, weighted average (diluted) | 221+13.2%— | 195+24.1%— | 157+9.6%— | 143+5.4%— | 136+12.8%— | 120+19.1%— | 101+249%— | 29—— | |
| Dividends per share | 0.00—— | 0.00—— | 0.00—— | 0.00—— | 0.00—— | 0.00—— | 0.00—— | 0.00—— | |
| Balance sheet | |||||||||
| Cash and cash equivalents | 52−31.3%12.4% | 75−9.5%13.7% | 83+34.3%12.9% | 62−64.3%7.5% | 173−5.5%16.5% | 183+4.7%14.9% | 175+89.5%24.4% | 92—11.9% | |
| Short-term investments | 199−8.6%47.7% | 217−40.6%39.6% | 366−19.7%56.9% | 455+60.4%55.4% | 284−55.9%27.0% | 645+81.4%52.5% | 355−3.1%49.5% | 367—47.4% | |
| Other current assets | 7.5−30.9%1.8% | 11+4.7%2.0% | 10−9.4%1.6% | 12−18.0%1.4% | 14−18.6%1.3% | 17+22.6%1.4% | 14+63.3%2.0% | 8.6—1.1% | |
| Current assets | 258−15.0%62.0% | 303−33.9%55.3% | 459−13.2%71.4% | 529+12.2%64.4% | 471−44.2%44.9% | 845+55.2%68.8% | 545+16.4%75.9% | 468—60.5% | |
| Property, plant and equipment | 73−15.4%17.5% | 86−13.5%15.7% | 99−11.8%15.5% | 113−8.3%13.7% | 123+3.5%11.7% | 119+111%9.7% | 56+557%7.9% | 8.6—1.1% | |
| Right-of-use (leased) assets | 40−11.8%9.6% | 45−29.0%8.2% | 64−23.8%9.9% | 84+44.0%10.2% | 58+40.5%5.5% | 41−7.2%3.4% | 44+34.8%6.2% | 33—4.3% | |
| Other intangible assets | — | — | — | — | — | 0−100%0.0% | 0.2−80.0%0.0% | 0.8—0.1% | |
| Long-term investments | — | — | — | — | — | — | 58−77.7%8.1% | 262—33.9% | |
| Total assets | 416−24.2%100% | 549−14.6%100% | 643−21.8%100% | 822r817−21.8%100% | 1,051r1,039−14.4%100% | 1,228+71.1%100% | 718−7.2%100% | 774—100% | |
| Accounts payable | 4.3−20.8%1.0% | 5.4−8.5%1.0% | 5.9−57.5%0.9% | 14+35.4%1.7% | 10−1.3%1.0% | 10+12.3%0.8% | 9.3−25.0%1.3% | 12—1.6% | |
| Current liabilities | 33−8.5%7.8% | 36−4.2%6.5% | 37−31.0%5.8% | 54r55+12.2%6.5% | 48r48−49.2%4.6% | 94+185%7.7% | 33+12.3%4.6% | 29—3.8% | |
| Lease liabilities (non-current) | 75−9.9%18.0% | 83−5.8%15.2% | 88−7.1%13.7% | 95+36.0%11.6% | 70+37.6%6.7% | 51−1.1%4.1% | 51+49.0%7.2% | 34—4.5% | |
| Total liabilities | 123−2.5%29.7% | 127−3.1%23.1% | 131−15.6%20.3% | 155r151+23.1%18.8% | 126r122−15.2%12.0% | 148+66.9%12.1% | 89+25.6%12.4% | 71—9.1% | |
| Retained earnings | −2,011—−483% | −1,820—−332% | −1,562—−243% | −1,235r−1,236—−150% | −895r−903—−85.1% | −713r−646—−58.0% | −396—−55.2% | −212—−27.3% | |
| Shareholders' equity | 293−30.7%70.3% | 422−17.6%76.9% | 512−23.2%79.7% | 667r666−27.9%81.2% | 925r916−8.7%88.0% | 1,013r1,080+61.1%82.5% | 629−10.5%87.6% | 703—90.9% | |
| Total liabilities and equity | 416−24.2%100% | 549−14.6%100% | 643−21.8%100% | 822r817−21.8%100% | 1,051r1,039−14.4%100% | 1,228+71.1%100% | 718−7.2%100% | 774—100% | |
| Shares outstanding | 229+8.1%— | 212+25.8%— | 169+16.8%— | 144+1.3%— | 143+1.5%— | 140+13.0%— | 124+2.3%— | 121—— | |
| Cash-flow statement | |||||||||
| Depreciation and amortization | 12−9.4%— | 14−3.9%61995% | 14r14−0.7%14946% | 14+36.2%9167% | 11+41.9%9.2% | 7.4+60.9%— | 4.6+360%— | 1.0—— | |
| Share-based compensation | 38−27.3%— | 52−21.5%235195% | 66−21.1%69422% | 84+3.4%53590% | 81+23.8%70.8% | 65+41.7%— | 46+148%— | 19—— | |
| Cash from operating activities | −149—— | −200—−910455% | −238—−250245% | −221—−141358% | −185—−162% | −115—— | −137—— | −45—— | |
| Capital expenditure | −0.4—— | −0.7—−3155% | −1.5—−1596% | −5.2—−3328% | −21—−18.8% | −66—— | −51—— | −3.2—— | |
| Cash from investing activities | 96+26.3%— | 76−53.6%344036% | 163+53.8%171883% | 106−35.1%68051% | 164—143% | −505−408%— | 164—— | −633—— | |
| Shares issued | — | — | 91—95907% | 0—0.0% | 0−100%0.0% | 596r622—— | 0r54−100%— | 344—— | |
| Cash from financing activities | 30−74.2%— | 117+21.9%530341% | 96+3144%100732% | 3.0−75.3%1891% | 12−98.1%10.5% | 634+975%— | 59−92.4%— | 771—— | |
| Change in cash | −24—— | −7.9−137%−36077% | 21—22369% | −111—−71417% | −9.2−169%−8.1% | 13−84.4%— | 86−8.6%— | 94—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | 0—— | 4.6—100% | — | 0*—— | 0—— | 0—— | 0−100%— | 0*−100%— | 0—— | 0—— | 0.0—100% | 0.0*—100% | |
| Research and development | 133−19.9%— | 42+34.6%— | 31−23.5%662% | 32−36.2%— | 29*−36.3%— | 31−30.3%— | 40−20.3%— | 50−3.9%— | 45*−17.7%— | 45—— | 50—— | 52—237541% | 55*—260290% | |
| General and administrative | 62+5.2%— | 13−6.4%— | 21+45.9%449% | 14−6.0%— | 14*−11.3%— | 14−15.9%— | 14−11.2%— | 15−13.2%— | 16*−9.9%— | 16—— | 16—— | 17—78486% | 17*—82019% | |
| Operating expenses | 195−14.3%— | 55+22.0%— | 52−9.3%1111% | 46−29.3%— | 42*−29.9%— | 45−37.4%— | 57−20.5%— | 65−6.2%— | 60*−28.9%— | 72—— | 71—— | 70—316027% | 85*—405381% | |
| Operating income | −190—— | −55—— | −47—−1011% | −46—— | −42*—— | −45—— | −57—— | −65—— | −60*—— | −72—— | −71—— | −70—−315927% | −85*—−405281% | |
| Interest expense and finance costs | 1.3+58.4%— | 0.4+10.2%— | 0.3+28.0%7.4% | 0.3+100%— | 0.3*+286%— | 0.3+244%— | 0.3—— | 0.2—— | 0.1*—— | 0.1—— | 0—— | 0—0.0% | 0*—0.0% | |
| Share of profit of associates | — | — | — | — | 0*—— | 0*—— | 0*−100%— | 0—— | 0*—— | −1.1*—— | 0.4*—— | −0.9—−4223% | −2.8*—−13362% | |
| Other non-operating income (expense) | 16−0.5%— | 4.4+26.4%— | 4.2−27.8%91.4% | 3.5−36.1%— | 3.6*+262%— | 3.5−36.1%— | 5.9+15.8%— | 5.5+21.2%— | 1.0*—— | 5.5—— | 5.1—— | 4.5—20473% | −0.7*—−3186% | |
| Net income including minority interests | −174—— | −50*—— | −43*—−920% | −43—— | −39*—— | −41*—— | −51*—— | −60—— | −60*—— | −66*—— | −66*—— | −65—−295455% | −86*—−408467% | |
| Net income attributable to shareholders | −174—— | −50—— | −43—−920% | −43—— | −39*—— | −41—— | −51—— | −60—— | −60*—— | −66—— | −66—— | −65—−295455% | −86*—−408467% | |
| Earnings per share, basic | — | -0.15—— | -0.13—— | -0.18—— | — | -0.19—— | -0.23—— | -0.28—— | — | -0.32—— | -0.35—— | -0.38—— | — | |
| Earnings per share, diluted | — | -0.15—— | -0.13—— | -0.18—— | — | -0.19—— | -0.23—— | -0.28—— | — | -0.32—— | -0.35—— | -0.38—— | — | |
| Shares, weighted average (basic) | 346+55.9%— | 346+55.9%— | 329+50.2%— | 240+11.6%— | — | 222+6.1%— | 219+15.2%— | 215+27.3%— | — | 209—— | 190—— | 169—— | — | |
| Shares, weighted average (diluted) | 346+55.9%— | 346+55.9%— | 329+50.2%— | 240+11.6%— | — | 222+6.1%— | 219+15.2%— | 215+27.3%— | — | 209—— | 190—— | 169—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 29—5.7% | 29−22.6%5.7% | 39−26.2%7.0% | 30−28.6%7.7% | 52−31.3%12.4% | 38−26.2%8.6% | 52−69.3%11.1% | 42−16.8%8.4% | 75−9.5%13.7% | 51—8.7% | 171—26.4% | 51—8.7% | 83—12.9% | |
| Short-term investments | 264—51.6% | 264+23.0%51.6% | 294+33.1%53.4% | 237−0.4%59.7% | 199−8.6%47.7% | 214−10.8%48.7% | 221−19.4%46.9% | 238−28.8%46.8% | 217−40.6%39.6% | 240—40.8% | 274—42.4% | 334—56.9% | 366—56.9% | |
| Other current assets | 6.9—1.3% | 6.9−19.4%1.3% | 7.4−22.4%1.3% | 6.4−44.4%1.6% | 7.5−30.9%1.8% | 8.5−33.7%1.9% | 9.5−23.7%2.0% | 12+9.8%2.3% | 11+4.7%2.0% | 13—2.2% | 12—1.9% | 11—1.8% | 10—1.6% | |
| Current assets | 300—58.6% | 300+15.0%58.6% | 340+20.3%61.8% | 273−6.3%69.0% | 258−15.0%62.0% | 261−14.4%59.3% | 283−38.2%60.1% | 292−26.3%57.4% | 303−33.9%55.3% | 304—51.7% | 457—70.7% | 395—67.4% | 459—71.4% | |
| Property, plant and equipment | 65—12.7% | 65−14.6%12.7% | 67−14.6%12.2% | 70−15.6%17.7% | 73−15.4%17.5% | 76−14.7%17.3% | 79−14.4%16.8% | 83−13.5%16.3% | 86−13.5%15.7% | 89—15.1% | 92—14.2% | 96—16.4% | 99—15.5% | |
| Right-of-use (leased) assets | 37—7.2% | 37−10.5%7.2% | 38−10.1%6.9% | 39−11.9%9.8% | 40−11.8%9.6% | 41−11.6%9.3% | 42−28.1%8.9% | 44−31.6%8.7% | 45−29.0%8.2% | 46—7.9% | 58—9.0% | 64—11.0% | 64—9.9% | |
| Total assets | 511—100% | 511+16.3%100% | 550+16.9%100% | 396−22.1%100% | 416−24.2%100% | 440−25.4%100% | 471−27.3%100% | 508−13.4%100% | 549−14.6%100% | 589—100% | 647—100% | 586—100% | 643—100% | |
| Accounts payable | 8.8—1.7% | 8.8+137%1.7% | 6.0+22.9%1.1% | 4.9−2.5%1.2% | 4.3−20.8%1.0% | 3.7−32.8%0.8% | 4.9−62.5%1.0% | 5.1−12.5%1.0% | 5.4−8.5%1.0% | 5.5—0.9% | 13—2.0% | 5.8—1.0% | 5.9—0.9% | |
| Current liabilities | 38—7.5% | 38+20.9%7.5% | 32+0.2%5.8% | 28−5.6%7.2% | 33−8.5%7.8% | 32−2.3%7.2% | 32−15.1%6.7% | 30−2.8%5.9% | 36−4.2%6.5% | 33—5.5% | 37—5.8% | 31—5.3% | 37—5.8% | |
| Lease liabilities (non-current) | 68—13.3% | 68−11.8%13.3% | 70−11.2%12.8% | 73−10.7%18.3% | 75−9.9%18.0% | 77−9.4%17.5% | 79−8.9%16.8% | 81−8.6%16.0% | 83−5.8%15.2% | 85—14.5% | 87—13.4% | 89—15.2% | 88—13.7% | |
| Total liabilities | 119—23.2% | 119−4.6%23.2% | 114−9.6%20.7% | 117−4.5%29.6% | 123−2.5%29.7% | 124−0.7%28.3% | 126−4.4%26.8% | 123−1.9%24.1% | 127−3.1%23.1% | 125—21.3% | 132—20.4% | 125—21.3% | 131—20.3% | |
| Retained earnings | −2,146—−420% | −2,146—−420% | −2,096—−381% | −2,053—−519% | −2,011—−483% | −1,972—−448% | −1,930—−410% | −1,880—−370% | −1,820—−332% | −1,760—−299% | −1,694—−262% | −1,627—−278% | −1,562—−243% | |
| Shareholders' equity | 393—76.8% | 393+24.5%76.8% | 436+26.6%79.3% | 279−27.6%70.4% | 293−30.7%70.3% | 315−32.0%71.7% | 345−33.1%73.2% | 385−16.5%75.9% | 422−17.6%76.9% | 464—78.7% | 515—79.6% | 461—78.7% | 512—79.7% | |
| Total liabilities and equity | 511—100% | 511+16.3%100% | 550+16.9%100% | 396−22.1%100% | 416−24.2%100% | 440−25.4%100% | 471−27.3%100% | 508−13.4%100% | 549−14.6%100% | 589—100% | 647—100% | 586—100% | 643—100% | |
| Shares outstanding | 346—— | 346+55.2%— | 345+56.9%— | 245+12.0%— | 229+8.1%— | 223+6.5%— | 220+5.3%— | 219+28.2%— | 212+25.8%— | 210—— | 209—— | 170—— | 169—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 11−11.0%— | 2.6*−16.5%— | 2.6*−14.8%57.0% | 2.9−7.4%— | 3.1*−5.4%— | 3.1*−3.4%— | 3.1*−14.8%— | 3.1−12.8%— | 3.2*−7.0%— | 3.2*—— | 3.6*—— | 3.6—16159% | 3.5r3.5*—16557% | |
| Share-based compensation | 36−15.4%— | 7.0−18.8%— | 12+43.2%268% | 8.3−32.1%— | 8.1*−36.8%— | 8.7−35.4%— | 8.7−35.9%— | 12+2.1%— | 13*−15.5%— | 13r13—— | 14—— | 12r12—54200% | 15*—72538% | |
| Cash from operating activities | −109—— | −36*—— | −32*—−690% | −13—— | −28*—— | −30*—— | −39*—— | −53—— | −37*—— | −44*—— | −64*—— | −56—−254086% | −54*—−255748% | |
| Capital expenditure | −0.2—— | −0.0*—— | −0.2*—−3.2% | −0.0—— | 0*—— | −0.2*—— | −0.0*—— | −0.1—— | −0.3*—— | −0.4*—— | 0*—— | −0.0—−36.4% | −0.2*—−862% | |
| Cash from investing activities | −117−200%— | 26*+119%— | −148*−437%−3180% | −30−579%— | 34*−38.8%— | 12*—— | 44*−41.3%— | 6.2−72.1%— | 55*−18.6%— | −76*—— | 75*—— | 22—100605% | 67*—321243% | |
| Shares issued | — | — | — | — | — | — | — | 10—— | — | — | — | 0—0.0% | 0*—0.0% | |
| Cash from financing activities | 217+676%— | 0.6*−80.0%— | 188*+3604%4049% | 21+51.0%— | 7.9*+36.8%— | 3.2*+377%— | 5.1*−95.3%— | 14+748%— | 5.7*+3605%— | 0.7*—— | 109*—— | 1.7—7500% | 0.2*—738% | |
| Change in cash | −8.5—— | −9.4*—— | 8.3*−15.8%179% | −21—— | 14*−42.1%— | −15*—— | 9.9*−91.7%— | −33—— | 24*+72.4%— | −119*—— | 120*—— | −32—−145982% | 14*—66233% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Allogene Therapeutics, Inc. sells: revenue by product line, fiscal 2024#
As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Reportable$0 M100%—
Source: SEC annual report (XBRL data) · as of Dec 31, 2024
Executive pay at Allogene Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dr. Chang | $6.1 M | $1.9 M | $2.3 M | $22 |
| 2024Zachary Roberts | $4.5 M | $872 K | $2.0 M | $34 |
| 2023Zachary Roberts | $14.1 M | $1.3 M | $7.0 M | $51 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Allogene Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 4 · Material agreement 3 · Agreement ended 1 · Shareholder vote 3 · Results announced 11
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Material agreementAgreement endedResults announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2018 | $412 M | No. 1 | $250 million to $1 billion | 23 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Allogene Therapeutics, Inc.#
1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $225 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior Manager, Quality and Regulatory SystemsComputer and Information Systems Managers | 1 | $225 K |
Where: South San Francisco, CA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 1 | 1 | $225 K | 1 |
| FY2024 | 1 | 1 | $129 K | 1 |
| FY2023 | 3 | 3 | $177 K | 3 |
| FY2022 | 6 | 6 | $157 K | 6 |
| FY2021 | 2 | 2 | $129 K | 2 |
| FY2020 | 2 | 2 | $160 K | 2 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Allogene Therapeutics, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 22% of workforce | Restructuring planSEC 8-K | “On January 4, 2024, the Company’s Board of Directors approved a reduction in the Company’s workforce of approximately 22% of the Company’s employees in connection with the Company’…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
Discuss Allogene Therapeutics, Inc.#
3 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 5 November 2026automatic update · Nov 5, 2026
Allogene Therapeutics, Inc. announced results on 5 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $50 million.
- Insider trading in October 2026automatic update · Oct 31, 2026
Directors and officers of Allogene Therapeutics, Inc. reported open-market trades for October 2026 (SEC Forms 4 and 5): 1 insider sold shares worth about $48,698 in 1 trade. Awards, option exercises and shares withheld for tax are not counted.
- Mutual funds: 136 funds hold $201 millionautomatic update · Jul 31, 2026
136 mutual funds in 1 country hold shares of Allogene Therapeutics, Inc. worth $201 million, about 28.1% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 91 funds added shares and 22 sold; on balance they bought $95 million. Share splits are not counted as trading.
How Allogene Therapeutics, Inc. compares in Biotechnology
- Market cap$450 M · higher than 56% of 726
- Revenue$0 M · higher than 0% of 647
- Revenue growth-80.0% · higher than 6% of 438
- Price / book1.5× · lower than 66% of 534
- FCF yield-33.2% · higher than 33% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Allogene Therapeutics, Inc.🇺🇸 | $450 M | — | — | -80.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, value.today research, SEC filing.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Allogene Therapeutics, Inc.? Verify and update this profile — free
Show Allogene Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.